Novavax Inc. (NVAX)
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NVAX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.85B
- EPS (TTM)
- -$1.57
- Dividend yield
- None
- 52-week range
- 6.20 – 13.39
- Day range
- 10.90 – 11.75
- Volume / Avg
- 8.36M / 5.11M
- Beta
- —
- Shares outstanding
- 164.95M
- Next earnings
- Nov 5, 2026
52-week range
NVAX stock today
Shares of Novavax (NVAX) finished lower on Oct 7 at $11.22, a drop of 0.88% or $0.10 per share, versus the S&P 500's 0.22% decline. Shares are 16.2% below their 52-week high of $13.39, set on Oct 5, 2026 and 81.0% above the 52-week low of $6.20, in the middle of the past year's range. NVAX is up 67.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 21.7%.
Novavax has posted a net loss over the last twelve months (EPS of -$1.57), so its P/E ratio is not meaningful. Novavax's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Novavax
Company profileNovavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. John Charles Jacobs M.B.A.
- Headquarters
- Gaithersburg, MD
- Employees
- 749
- Website
- novavax.com
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$14.00+24.78%
- Strong buy 0
- Buy 5
- Hold 1
- Sell 1
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.37
NVAX news
All NVAX newsNovavax peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MESOMesoblast Limited ADR | 13.94 | +2.42% | $1.81B | vs NVAX |
| VIRVir Biotechnology Inc. | 11.52 | -0.69% | $1.95B | vs NVAX |
| VCELVericel Corporation | 40.74 | +1.72% | $2.09B | vs NVAX |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs NVAX |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs NVAX |
| IMCRImmunocore Holdings plc ADR | 29.41 | -0.47% | $1.51B | vs NVAX |
| ADMAADMA Biologics Inc | 10.14 | -0.39% | $2.27B | vs NVAX |
| MAZEMaze Therapeutics Inc. | 26.25 | -0.68% | $1.46B | vs NVAX |
Indexes, lists and sector
Novavax stock FAQ
What is Novavax's stock price today?
NVAX last traded at $11.22 as of Oct 7, 4:00 PM EDT, down 0.88% on the day. Prices are delayed at least 15 minutes.
Does Novavax pay a dividend?
No. Novavax does not currently pay a regular cash dividend.
When is Novavax's next earnings date?
Novavax is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.37.
Who is Novavax's CEO?
Mr. John Charles Jacobs M.B.A. is the chief executive officer of Novavax Inc., which has about 749 employees.
Has NVAX ever split its stock?
Yes. The most recent NVAX stock split was a 1-for-20 split on May 10, 2019.
What is the NVAX 52-week high?
The 52-week high for NVAX is $13.39 and the 52-week low is $6.20. The stock is currently 16.2% below its high.